REFERENCES
1. Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-62.
2. Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990;33:1135-6.
3. Kallenberg CGM. Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis. Curr Opin Rheumatol 2016;28:8-14.
4. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-23.
5. Nishi R, Koike H, Ohyama K, et al. Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA. Neurology 2020;94:E1726-37.
6. Holle JU, Gross WL, Holl-Ulrich K, et al. Prospective long-term follow-up of patients with localised Wegener’s granulomatosis: Does it occur as persistent disease stage? Ann Rheum Dis 2010;69:1934-9.
7. Felicetti M, Cazzador D, Padoan R, et al. Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes. Clin Rheumatol 2018;37:1075-83.
8. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-7.
10. Nishi R, Koike H, Ohyama K, et al. Association between IL-5 levels and the clinicopathologic features of eosinophilic granulomatosis with polyangiitis. Neurology 2021;96:226-9.
11. Bligny D, Mahr A, Toumelin P Le, et al. Predicting mortality in systemic Wegener’s granulomatosis: a survival analysis based on 93 patients. Arthritis Rheum 2004;51:83-91.
12. Rahmattulla C, De Lind van Wijngaarden RAF, Berden AE, et al. Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. Rheumatology (Oxford) 2015;54:899-907.
13. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005;143:621.
14. Trimarchi M, Sinico RA, Teggi R, et al. Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener’s). Autoimmun Rev 2013;12:501-5.
15. Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013;65:270-81.
16. Durel C-A, Berthiller J, Caboni S, et al. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Arthritis Care Res (Hoboken) 2016;68:374-87.
17. Millet A, Pederzoli-Ribeil M, Guillevin L, et al. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis 2013;72:1273-9.
18. Gubbels SP, Barkhuizen A, Hwang PH. Head and neck manifestations of wegener’s granulomatosis. Otolaryngol Clin North Am 2003;36:685-705.
19. Rasmussen N. Management of the ear, nose, and throat manifestations of Wegener granulomatosis: an otorhinolaryngologist’s perspective. Curr Opin Rheumatol 2001;13:3-11.
20. Kwan ASL, Rose GE. Lacrimal drainage surgery in Wegener’s granulomatosis. Br J Ophthalmol 2000;84:329-31.
21. Kühn D, Hospowsky C, Both M, et al. Manifestation of granulomatosis with polyangiitis in head and neck. Clin Exp Rheumatol 2018;36 Suppl 111:78-84.
22. Holme SS, Moen JM, Kilian K, et al. Development of CT-based methods for longitudinal analyses of paranasal sinus osteitis in granulomatosis with polyangiitis. BMC Med Imaging 2019;19:13.
23. Muhle C, Reinhold-Keller E, Richter C, et al. MRI of the nasal cavity, the paranasal sinuses and orbits in Wegener’s granulomatosis. Eur Radiol 1997;7:566-70.
24. Wojciechowska J, Krajewski W, Krajewski P, et al. Granulomatosis With polyangiitis in otolaryngologist practice: a review of current knowledge. Clin Exp Otorhinolaryngol 2016;9:8-13.
25. Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol 2006;126:503-9.
26. Olsen KD, Neel HB, Deremee RA, et al. Nasal manifestations of allergic granulomatosis and angiitis (Churg-Strauss syndrome). Otolaryngol Head Neck Surg 1980;88:85-9.
27. Suzuki M, Nakazono A, Morita S, et al. Comparison of clinical characteristics of the nasal manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) and eosinophilic chronic rhinosinusitis (ECRS). Allergol Int 2021;70:143-4.
28. Brescia G, Padoan R, Schiavon F, et al. Nasal polyps in eosinophilic granulomatosis with polyangiitis: structured histopathology and CD105 expression. Am J Otolaryngol Head Neck Med Surg 2020;41:102661.
29. Contro G, Brescia G, Alessandrini L, et al. Neutrophil infiltrates and eosinophil aggregates in chronic rhinosinusitis with nasal polyps and EGPA. Clin Rheumatol ;2021:40:1949-57.
30. Brescia G, Schiavon F, Nicolè L, et al. No differences in nasal tissue inflammatory cells and adhesion molecules (iCAM-1 and vCAM-1) based on the comparison of EGPA with eosinophilic chronic sinusitis with polyposis. Am J Rhinol Allergy 2019;33:395-402.
31. Rahne T, Clauß F, Plontke SK, et al. Prevalence of hearing impairment in patients with rheumatoid arthritis, granulomatosis with polyangiitis (GPA, Wegener’s granulomatosis), or systemic lupus erythematosus. Clin Rheumatol 2017;36:1501-10.
32. Martinez Del Pero M, Walsh M, Luqmani R, et al. Long-term damage to the ENT system in Wegener’s granulomatosis. Eur Arch Otorhinolaryngol 2011;268:733-9.
33. Girasoli L, Cazzador D, Padoan R, et al. Update on vertigo in autoimmune disorders, from diagnosis to treatment. J Immunol Res 2018;2018:5072582.
34. Nogaki T, Keskin N, Azuma T, et al. Quantitative assessment of vestibular otopathology in granulomatosis with polyangitis: a temporal bone study. Laryngoscope Investig Otolaryngol 2018;3:473-7.
35. Ono N, Niiro H, Ueda A, et al. Characteristics of MPO-ANCA-positive granulomatosis with polyangiitis: a retrospective multi-center study in Japan. Rheumatol Int 2015;35:555-9.
36. Schirmer JH, Wright MN, Herrmann K, et al. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener’s) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German vasculitis referral center. Arthritis Rheumatol 2016;68:2953-63.
37. Ralli M, D’Aguanno V, Di Stadio A, et al. Audiovestibular symptoms in systemic autoimmune diseases. J Immunol Res 2018;2018:5798103.
38. Seccia V, Fortunato S, Cristofani-Mencacci L, et al. Focus on audiologic impairment in eosinophilic granulomatosis with polyangiitis. Laryngoscope 2016;126:2792-7.
39. Nakamaru Y, Takagi D, Suzuki M, et al. Otologic and rhinologic manifestations of eosinophilic granulomatosis with polyangiitis. Audiol Neurotol 2016;21:45-53.
40. Harabuchi Y, Kishibe K, Tateyama K, et al. Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society. Auris Nasus Larynx 2021;48:2-14.
41. Harabuchi Y, Kishibe K, Tateyama K, et al. Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): a retrospective analysis of 235 patients from a nationwide survey in Japan. Mod Rheumatol 2017;27:87-94.
42. Girard C, Charles P, Terrier B, et al. Tracheobronchial stenoses in granulomatosis with polyangiitis (Wegener’s): a report on 26 cases. Medicine (Baltimore) 2015;94:e1088.
43. Fijolek J, Wiatr E, Gawryluk D, et al. Intratracheal dilation-injection technique in the treatment of granulomatosis with polyangiitis patients with subglottic stenosis. J Rheumatol 2016;43:2042-8.
44. Seccia V, Cristofani-Mencacci L, Dallan I, et al. Eosinophilic granulomatosis with polyangiitis and laryngeal involvement: Review of the literature and a cross-sectional prospective experience. J Laryngol Otol 2018;132:619-23.
45. Del Pero MM, Jayne D, Chaudhry A, et al. Long-term outcome of airway stenosis in granulomatosis with polyangiitis (Wegener Granulomatosis): An observational study. JAMA Otolaryngol Head Neck Surg 2014;140:1038-44.
46. Jordan NP, Verma H, Siddiqui A, et al. Morbidity and mortality associated with subglottic laryngotracheal stenosis in granulomatosis with polyangiitis (Wegener’s granulomatosis): a single-centre experience in the United Kingdom. J Laryngol Otol 2014;128:831-7.
47. Quinn KA, Gelbard A, Sibley C, et al. Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. Rheumatology (Oxford) 2019;58:2203-11.
48. Guardiani E, Moghaddas HS, Lesser J, et al. Multilevel airway stenosis in patients with granulomatosis with polyangiitis (Wegener’s). Am J Otolaryngol Head Neck Med Surg 2015;36:361-3.
49. Terrier B, Dechartres A, Girard C, et al. Granulomatosis with polyangiitis: Endoscopic management of tracheobronchial stenosis: Results from a multicentre experience. Rheumatology (Oxford) 2015;54:1852-7.
50. Alam DS, Rahul S, Raj S, et al. Upper airway manifestations of granulomatosis with polyangiitis. Cleve Clin J Med 2012;79:16-21.
51. Zycinska K, Wardyn K, Zielonka TM, et al. Subglottic and tracheal stenosis due to Wegener’s granulomatosis. Adv Exp Med Biol 2013;755:221-4.
52. Church AC, Goldsmith K, Sivasothy P. Aspiration and development of subglottic stenosis in patients with Wegeners granulomatosis. J Laryngol Otol 2010;124:393-6.
53. Gluth MB, Shinners PA, Kasperbauer JL. Subglottic stenosis associated with Wegener’s granulomatosis. Laryngoscope 2003;113:1304-7.
54. Marroquín-Fabián E, Ruiz N, Mena-Zúñiga J, et al. Frequency, treatment, evolution, and factors associated with the presence of tracheobronchial stenoses in granulomatosis with polyangiitis. Retrospective analysis of a case series from a single respiratory referral center. Semin Arthritis Rheum 2019;48:714-9.
55. Sharma A, Deshmukh S, Dabholkar J. ENT manifestations of Wegeners granulomatosis. Otolaryngol Pol 2013;67:257-60.
56. Langford CA, Sneller MC, Hallahan CW, et al. Clinical features and therapeutic management of subglottic stenosis in patients with Wegener’s granulomatosis. Arthritis Rheum 1996;39:1754-60.
57. Martinez Del Pero M, Rasmussen N, Chaudhry A, et al. Structured clinical assessment of the ear, nose and throat in patients with granulomatosis with polyangiitis (Wegener’s). Eur Arch Otorhinolaryngol 2013;270:345-54.
58. Taylor SC, Clayburgh DR, Rosenbaum JT, Schindler JS. Clinical manifestations and treatment of idiopathic and Wegener granulomatosis-associated subglottic stenosis. JAMA Otolaryngol Head Neck Surg 2013;139:76-81.
59. Nico MMS, Pinto NT, Lourenço SV. From strawberry gingivitis to palatal perforation: The clinicopathological spectrum of oral mucosal lesions in granulomatosis with polyangiitis. J Oral Pathol Med 2020;49:443-9.
60. Xing X, Zhang T, Wang X. Pediatric Wegener’s granulomatosis with oral ulcers and progressive periodontitis: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011:112.
61. Knight JM, Hayduk MJ, Summerlin DJ, et al. “Strawberry” gingival hyperplasia: a pathognomonic mucocutaneous finding in Wegener granulomatosis. Arch Dermatol 2000;136:171-3.
62. Eufinger H, Machtens E, Akuamoa-Boateng E. Oral manifestations of Wegener’s granulomatosis. Review of the literature and report of a case. Int J Oral Maxillofac Surg 1992;21:50-3.
63. Hernández G, Serrano C, Porras L, et al. Strawberry-like gingival tumor as the first clinical sign of Wegener’s granulomatosis. J Periodontol 2008;79:1297-303.
64. Hanisch M, Fröhlich LF, Kleinheinz J. Gingival hyperplasia as first sign of recurrence of granulomatosis with polyangiitis (Wegener’s granulomatosis): case report and review of the literature. BMC Oral Health 2016;17:33.
65. Trimarchi M, Bondi S, Della Torre E, Terreni MR, Bussi M. Palate perforation differentiates cocaine-induced midline destructive lesions from granulomatosis with polyangiitis. Acta Otorhinolaryngol Ital 2017;37:281-5.
66. Nelson RE, Hildrew DM, Deblieux T, et al. Wegener’s Granulomatosis presenting as a parapharyngeal mass. J Louisiana State Med Soc Off organ Louisiana State Med Soc 2016;168:60-2.
67. Lee PY, Adil EA, Irace AL, et al. The presentation and management of granulomatosis with polyangiitis (Wegener’s Granulomatosis) in the pediatric airway. Laryngoscope 2017;127:233-40.
68. Shenavandeh S, Petramfar P. Three atypical manifestations of granulomatosis with polyangiitis: lateral medullary syndrome, anterior cheek mass and melting scleritis of eye. Reumatologia 2017;55:145-50.
69. Masuda T, Izumi Y, Takeshita H, et al. Granulomatosis with polyangiitis presenting as a choroidal tumor. Case Rep Rheumatol 2015;2015:271823.
70. Spanuchart I, Zungsontiporn N, O-charoen P, et al. Granulomatosis with polyangiitis: a case of nasal mass, necrotic lung, and normal kidneys. Hawaii J Med Public Health 2015;74:27-9.
71. Coates ML, Martinez Del Pero M. Updates in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for the ENT surgeon. Clin Otolaryngol 2020;45:316-26.
72. Greco A, Marinelli C, Fusconi M, et al. Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol 2016;29:151-9.
73. Pendolino AL, Unadkat S, Zhang H, et al. The role of surgery in antineutrophil cytoplasmic antibody-associated vasculitides affecting the nose and sinuses: a systematic review. SAGE Open Med 2020;8:205031212093673.
74. Devaney KO, Travis WD, Hoffman G, et al. Interpretation of head and neck biopsies in Wegener’s granulomatosis. a pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990;14:555-64.
75. Seccia V, Baldini C, Latorre M, et al. Focus on the involvement of the nose and paranasal sinuses in Eosinophilic Granulomatosis with polyangiitis (Churg-Strauss Syndrome): nasal cytology reveals infiltration of eosinophils as a very common feature. Int Arch Allergy Immunol 2018;175:61-9.
77. D’Anza B, Langford CA, Sindwani R. Sinonasal imaging findings in Granulomatosis with polyangiitis (Wegener granulomatosis): a systematic review. Am J Rhinol Allergy 2017;31:16-21.
79. Carnevale C, Arancibia-Tagle D, Sarría-Echegaray P, et al. Head and neck manifestations of granulomatosis with polyangiitis: a retrospective analysis of 19 patients and review of the literature. Int Arch Otorhinolaryngol 2019;23:165-71.
80. Hernández-Rodríguez J, Hoffman GS, Koening CL. Surgical interventions and local therapy for Wegener’s granulomatosis. Curr Opin Rheumatol 2010;22:29-36.
81. Erickson VR, Hwang PH. Wegener’s granulomatosis: current trends in diagnosis and management. Curr Opin Otolaryngol Head Neck Surg 2007;15:170-6.
82. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583-94.
83. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
85. Stegeman CA, Cohen Tervaert JW, De Jong PE, et al. Trimethoprim-sulfamethoxazole (Co-Trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. N Engl J Med 1996;335:16-20.
86. Padoan R, Felicetti M, Gatto M, et al. Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study. Clin Exp Rheumatol 2020;38:188-94.
87. Raffray L, Guillevin L. Rituximab treatment of ANCA-associated vasculitis. Expert Opin Biol Ther 2020;20:899-910.
88. Okada M, Suemori K, Takagi D, et al. The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis. Auris Nasus Larynx 2019;46:38-42.
89. Durel C-A, Hot A, Trefond L, et al. Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford) 2019;58:1565-73.
90. Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener’s granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012;71:327-33.
91. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853-8.
92. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008;35:2017-23.
93. Pullerits R, Ljevak M, Vikgren J, et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of Antineutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Scand J Immunol 2012;76:411-20.
94. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017;376:1921-32.
95. Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008;58:586-94.
96. Pagnoux C, Groh M. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Expert Rev Clin Immunol 2016;12:1059-67.
97. Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Care Res 2007;57:686-93.
98. Nagase H, Ueki S, Fujieda S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int 2020;69:178-86.
99. Canzian A, Venhoff N, Urban ML, et al. Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study. Arthritis Rheumatol 2020;73:498-503.
100. Manka LA, Guntur VP, Denson JL, et al. Efficacy and safety of reslizumab in the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA). Ann Allergy Asthma Immunol 2021:S1081-1206(21)00097.
101. Guntur VP, Manka LA, Denson JL, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 2021;9:1186-93.
102. Padoan R, Chieco Bianchi F, Marchi MR, et al. Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract 2020;8:3225-7.e2.
103. Kita H. Eosinophils: Multifaceted biological properties and roles in health and disease. Immunol Rev 2011;242:161-77.
104. Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013;132:1086-96.
105. Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J 2018;52:1801393.
106. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011;154:573-82.
107. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020;146:595-605.
108. Goldstein S, Gabriel S, Kianifard F, et al. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: review of omalizumab clinical trials. Ann Allergy Asthma Immunol 2017;118:500-4.
109. Caruso C, Gencarelli G, Gaeta F, et al. Efficacy of omalizumab treatment in a man with occupational asthma and eosinophilic granulomatosis with polyangioitis. Ann Allergy Asthma Immunol 2018;120:209-11.
110. Aguirre-Valencia D, Posso-Osorio I, Bravo JC, et al. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol 2017;36:2159-62.
111. Detoraki A, Di Capua L, Varricchi G, et al. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma 2016;53:201-6.
112. Jachiet M, Samson M, Cottin V, et al. Anti-IgE monoclonal antibody (Omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol 2016;68:2274-82.
114. Puéchal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med 2008;19:364-6.
115. Basta F, Mazzuca C, Nucera E, et al. Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? Clin Exp Rheumatol 2020;38 Suppl 124:214-20.
116. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015;26:545-53.
117. Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: a systematic literature review. Autoimmun Rev 2021;20:102737.
118. Casal Moura M, Berti A, Keogh KA, et al. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. Clin Rheumatol 2020;39:1581-90.
119. Sattui SE, Lally L. Localized Granulomatous with polyangiitis (GPA): varied clinical presentations and update on treatment. Curr Allergy Asthma Rep 2020;20:56.
120. Holme SS, Moen JM, Kilian K, et al. Impact of paranasal sinus surgery in granulomatosis with polyangiitis: a longitudinal computed tomography study. Laryngoscope 2020;130:E460-8.
121. Unadkat SN, Pendolino AL, Kwame I, et al. Nasal reconstructive surgery for vasculitis affecting the nose: our two-centre international experience. Eur Arch Otorhinolaryngol 2020;277:3059-66.
122. Sahyouni R, Moshtaghi O, Abouzari M, et al. A case series of granulomatosis with polyangiitis primarily diagnosed by otological manifestations. Ann Otol Rhinol Laryngol 2019;128:263-6.
123. Srouji IA, Andrews P, Edwards C, et al. General and rhinosinusitis-related quality of life in patients with Wegener’s granulomatosis. Laryngoscope 2006;116:1621-5.
